Novavax shares rise after raised revenue guidance and Sanofi milestone
Novavax shares gained 8.8% in the afternoon after Q3 2026 results, a raised full-year revenue outlook and a $125 million Sanofi milestone, per stockstory.org.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of Novavax, a vaccine developer, rose 8.8% during the afternoon trading session, according to stockstory.org. The gain followed the company's third-quarter 2026 report, in which revenue reached $68 million and the net loss narrowed to $31 million from $202 million a year earlier.
Management lifted its full-year 2026 adjusted revenue guidance by $145 million, to a midpoint of $400 million. The company also collected a $125 million milestone payment after Sanofi started a Phase 3 combination vaccine trial in Europe.
why it matters
The stock has recorded 50 moves above 5% over the past year, so sharp swings are common for it. According to the report, the market views the update as meaningful but not as a shift in its view of the business. Shares are up 49.4% this year, yet at $10.65 they remain 16.9% below their 52-week high of $12.82 from October 2026.
tags
instruments
sources
- Novavax (NVAX) stock trades up, here is why — stockstory.org, 6 November 2026 at 19:20 UTC
- Celsius (CELH) stock trades up, here is why — stockstory.org, 6 November 2026 at 20:45 UTC
- Zevia (ZVIA) stock trades up, here is why — stockstory.org, 6 November 2026 at 20:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗